Objective: To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent. 
gynecologic oncology organizations and societies worldwide, as well as the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC).
Extensive inputs received via email were collated, and the literature was reviewed and evaluated, and eventually formulated into the staging that is presented here. Additionally, presentations, face-to-face meetings, and discussions and teleconferences were held on the sidelines of the European Society of Gynecologic Oncology meeting in Vienna, Austria 
| KEY AMENDMENTS TO STAGING OF CANCER OF THE CERVIX UTERI
The following amendments to the staging classification of carcinoma of the cervix uteri were made by the FIGO Committee for Gynecologic Oncology in 2018:
1. Allowing the use of any imaging modality and/or pathological findings for allocating the stage.
2.
In stage I, amendments to microscopic pathological findings and to size designations, allowing the use of imaging and/or pathological assessment of the size of the cervical tumor.
3.
In stage II, allowing the use of imaging and/or pathological assessment of size and extent of the cervical tumor.
4.
In stages I through III, allowing assessment of retroperitoneal lymph nodes by imaging and/or pathological findings and, if deemed metastatic, the case is designated as stage IIIC (with notation of method used for stage allocation).
5.
No recommendations for routine investigations, which are to be decided on the basis of clinical findings and standard of care.
| GENERAL RECOMMENDATIONS
1. The revised staging system does not mandate the use of a specific imaging technique, lymph node biopsy, or surgical assessment of the extent of tumor. In low-resourced conditions, clinicians can continue to assess the patient clinically as before.
a. The size of the primary tumor can be assessed by clinical evaluation (pre-or intraoperative), imaging, and/or pathological measurement.
b. Identification of lymph node metastasis should be accomplished using any imaging technique(s) and/or pathological assessment methods available to the provider, and the choice of technique is theirs.
2.
It is recommended that the method used for imaging (e.g., ultra- 
3.
It is recognized that there will be limitations for imaging findings in low-and lower-middle-income countries as a result of paucity, nonavailability, or inadequate access to extensive imaging services.
As in the previous staging, when in doubt, the lower staging should be assigned.
Box 1 FIGO staging of carcinoma of the cervix uteri (2018).
Stage I:
The carcinoma is strictly confined to the cervix uteri (extension to the corpus should be disregarded)
• IA Invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion <5 mm The carcinoma is strictly confined to the cervix uteri (extension to the corpus should be disregarded).
• 
| Controversial issues
• Presence of vascular/lymph space invasion: lymphovascular space invasion does not change the stage.
• Extension to the uterine corpus: involvement of the uterine body does not change the stage.
| Recommendations
• The size and extent of the primary tumor can be assessed by clinical evaluation (pre-or intraoperative), imaging, and/or pathological measurement.
• Methods of imaging may include ultrasound, CT, MRI, PET, PET-CT, MRI-PET, etc., based on local resources. 14-16 MRI has been shown to have the best sensitivity and specificity in assessing the size of the lesion. 17, 18 However, ultrasound has been shown to provide comparable information for staging in the hands of experienced operators.
19-21
• In operated patients, the histopathological examination will provide information about size and extent of lesion.
• The final stage is to be assigned after receiving all reports. The method of recording the size and assigning stage should be noted.
| STAGE II CLASSIFICATION
Cervical carcinoma invades beyond the uterus, but not to the lower third of the vagina or to the pelvic wall.
| Controversial issues
• Use of imaging for assessment of parametrial involvement: The utility of imaging for evaluation of parametrium and upper vagina is less clear. MRI has been shown to perform better than CT scan for parametrial assessment. • Involvement of ovary: Involvement of the ovary has been reported in <1% of cases of squamous cell carcinoma and in <5% of cases of non-squamous cell carcinoma in early stage cervical cancer.
22-24
Since it is often associated with the presence of other risk factors, there are limited data on its impact on survival as an independent risk factor. Presently, ovarian involvement does not change the stage.
| Recommendations
• Colposcopy may be used to assess the extent of vaginal involvement. Examination under anaesthesia may be useful to improve the accuracy of clinical assessment where imaging facilities are lacking
• As in stage I, the method used to assess tumor size and extent should be recorded.
| STAGE III CLASSIFICATION
The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney and/or involves pelvic and/or paraaortic lymph nodes.
• IIIA: Carcinoma involves the lower third of the vagina, with no extension to the pelvic wall.
• IIIB: Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney.
• The sensitivity of these modalities for detecting nodal metastasis varies from 60% to 88%, with specificity as high as 97%. [28] [29] [30] The role of PET-CT to detect lymph nodal metastasis has been studied in various centers and the results are promising.
31-35
In a case of radical surgery, pathological assessment of lymph nodes will be possible. Alternatively, there may be a practice/capability for imaging-guided fine needle aspiration cytology. A notation of 'r' or 'p' is to be given depending on whether the staging was assigned on the basis of imaging or pathology, respectively. An example is shown in Box 1.
This will enable prospective data collection regarding each method.
Absence of any notation indicates the use of clinical methods only.
| Controversial issues
• • Differentiating metastases from infection: In many countries with a high cervical cancer burden there is also a high burden of other infections (e.g., tuberculosis and HIV). In these endemic areas, there is a possibility of nodes being enlarged without metastases. The assessment of metastatic lymph nodes versus infected lymph nodes does not have clear radiological criteria.
• Sentinel lymph nodes: Sentinel lymph node dissection is commonly used in vulvar and endometrial cancer. In cervical cancer, good sensitivity and specificity has been reported with acceptable false negative rates.
36-40
Appropriate facilities and expertise should be available to validate and follow the protocol for the sentinel lymph node approach, which also requires good backup of pathology for ultrastaging and immunohistochemistry. Following the protocol is essential for this procedure.
| Recommendations
• Surgicopathological assessment of lymph node involvement requires advanced surgical skills, whether performed by conventional or minimally invasive surgery. Since 85% of cases presently occur in low-resource settings, the required professional skills and infrastructure facilities are presently not widely available.
Pathological confirmation is the gold standard but imaging can be used to interpret disease extent.
• The choice of imaging modality for nodal evaluation has not been fixed by FIGO. It depends upon the availability of the imaging modality and patients' affordability. Non-availability of an imaging modality should not be a reason for undue delay in initiation of treatment.
• FIGO does not define criteria to discriminate between malignancy and inflammation/infection on imaging, which is left to the discretion of the clinician. The clinician must opine on whether these look suspicious enough to upstage the case or not.
• The best available technology should be used for assessment, and the lowest appropriate stage should be assigned-i.e., when in doubt assign the lower stage.
• At the present time, lack of facilities universally is recognized and clinical assessment of staging with the use of other facilities as available is permissible. The method of assigning the stage is to be recorded and reported.
| STAGE IV CLASSIFICATION
The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous edema, as such, does not permit a case to be allotted to stage IV.
• IVA: Spread to adjacent organs
• IVB: Spread to distant organs
| Comment
Stage IV remains unchanged.
